Therefore, despite the challenges of treating older AML patients who had already failed prior therapy, the results suggest that they can benefit from olutasidenib, providing the rationale for further studies on the therapeutic role of this agent in R/R IDH1-mutated AML [143]. The gene discussed is IDH1; the disease is acute myeloid leukemia.